Tags: 
Expanding a product portfolio through the selection of additional indications can offer strategic growth opportunities. However, the process of selecting indications for portfolio expansion requires careful consideration of various factors. Here are few of them for your consideration:
- Synergy with Existing Capabilities: Building on established strengths can streamline development and increase the chances of success.
- Competition Landscape: Choose indications with opportunities for differentiation or where the company’s product could provide unique advantages.
- Patient Population: Evaluate whether the company’s product could address a specific subset of patients within the indication.
- Clinical and Regulatory Considerations: Assess the feasibility of conducting clinical trials, the likelihood of regulatory success, and potential challenges that might arise.
- Clinical Trial Design: Consider endpoint selection and patient recruitment feasibility.
- Health Economics and Reimbursement: Assess whether the company’s product can provide a clear value proposition that aligns with reimbursement trends and payer expectations.
- Portfolio Diversity: Aim for a balanced portfolio that covers a range of indications with varying risk profiles.
- Patient Impact: Choose indications where the company’s product can make a meaningful impact on patient outcomes and quality of life.
Visit BBCR Consulting Online to Learn More
#EarlyClinicalStrategy #PortfolioExpansion #ClinicalResearch #IndicationSelection #ClinicalTrialDesign #PortfolioDiversity #StreamlineDevelopment #Reimbursement #PatientImpact #CompetitiveLandscape
Specializing in rare disease, Boston Biotech Clinical Research works with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process. Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements.